Étude du mécanisme d'internalisation et des modalités d'action d'une prodrogue squalénée de la gemcitabine sous forme nanoparticulaire

The squalenoyl prodrug of gemcitabine is released from its nanoassemblies to enter cells by passive diffusion through the plasma membrane, facilitated by extracellular proteins. The bioconjugate is then progressively released from its intracellular membrane reservoirs into the cytoplasm and cleaved into gemcitabine, which is converted into its active metabolites. This original drug delivery pathway bypasses some of the resistance mechanisms that usually hamper the efficacy of gemcitabine.